Marker Therapeutics, Inc.
General ticker "MRKR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $18.3M (TTM average)
Marker Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -2.2%.
Estimated limits based on current volatility of 4.3%: low 1.23$, high 1.34$
Factors to consider:
- Total employees count: 8 (-88.1%) as of 2023
- Top business risk factors: Being a clinical stage company, Product candidates in clinical development, Regulatory and compliance, Clinical trial delays, Manufacturing scalability issues
- Current price 14.6% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.66$, 4.65$]
- 2025-12-31 to 2026-12-31 estimated range: [1.10$, 3.18$]
Financial Metrics affecting the MRKR estimates:
- Positive: with PPE of -2.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -34.53 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 0 > -0.66
Short-term MRKR quotes
Long-term MRKR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.51MM | $3.31MM | $6.59MM |
| Operating Expenses | $23.30MM | $17.89MM | $17.71MM |
| Operating Income | $-19.79MM | $-14.58MM | $-11.12MM |
| Non-Operating Income | $0.02MM | $0.54MM | $0.44MM |
| R&D Expense | $11.97MM | $10.42MM | $13.47MM |
| Income(Loss) | $-19.78MM | $-14.04MM | $-10.68MM |
| Taxes | $0.00MM | $0.00MM | $0.05MM |
| Other Income(Loss) | $-10.15MM | $5.81MM | $0.00MM |
| Profit(Loss)* | $-40.09MM | $-2.43MM | $-10.73MM |
| Stockholders Equity | $19.60MM | $14.05MM | $18.56MM |
| Assets | $34.42MM | $17.13MM | $22.02MM |
| Operating Cash Flow | $-26.97MM | $-16.44MM | $-10.91MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-4.95MM | $18.66MM | $0.00MM |
| Financing Cash Flow | $0.20MM | $1.11MM | $14.99MM |
| Earnings Per Share** | $-4.80 | $-0.28 | $-1.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.